Optimising Radiation Therapy Dose to the Swallowing Organs at Risk: An In Silico Study of feasibility for Patients with Oropharyngeal Tumours
- 5 Downloads
Recent evidence suggests that reducing radiotherapy dose delivered to specific anatomical swallowing structures [Swallowing Organs at Risk (SWOARs)] may improve swallowing outcomes post-treatment for patients with head and neck cancer. However, for those patients with tumours of the oropharynx, which typically directly overlap the SWOARs, reducing dose to these structures may be unachievable without compromising on the treatment of the disease. To assess the feasibility of dose reduction in this cohort, standard IMRT plans (ST-IMRT) and plans with reduced dose to the SWOARs (SW-IMRT) were generated for 25 oropharyngeal cancer patients (Brouwer et al. in Radiother Oncol 117(1):83–90, https://doi.org/10.1016/j.radonc.2015.07.041, 2015; Christianen et al. in Radiother Oncol 101(3):394–402, https://doi.org/10.1016/j.radonc.2011.05.015, 2011). ST-IMRT and SW-IMRT plans were compared for: mean dose to the SWOARs, volume of pharynx and larynx receiving 50 Gy and 60 Gy (V50 and V60 respectively) and overlap between the tumour volume and the SWOARs. Additionally, two different SWOARs delineation guidelines (Brouwer et al. in Radiother Oncol 117(1):83–90, https://doi.org/10.1016/j.radonc.2015.07.041, 2015; Christianen et al. in Radiother Oncol 101(3):394–402, https://doi.org/10.1016/j.radonc.2011.05.015, 2011) were used to highlight differences in calculated volumes between existing contouring guidelines. Agreement in SWOARs volumes between the two guidelines was calculated using a concordance index (CI). Despite a large overlap between the tumour and SWOARs, significant (p < 0.05) reductions in mean dose to 4 of the 5 SWOARs, and V50/V60 for the pharynx and larynx were achieved with SW-IMRT plans. Low CIs per structure (0.15–0.45) were found between the two guidelines highlighting issues comparing data between studies when different guidelines have been used (Hawkins et al. in Semin Radiat Oncol 28(1):46–52, https://doi.org/10.1016/j.semradonc.2017.08.002, 2018; Brodin et al. in Int J Radiat Oncol Biol Phys 100(2):391–407, https://doi.org/10.1016/j.ijrobp.2017.09.041, 2018). This study found reducing dose to the SWOARs is a feasible practice for patients with oropharyngeal cancer. However, future prospective research is needed to determine if the extent of dose reduction achieved equates to clinical benefits.
KeywordsHead and neck cancer Radiation therapy planning Swallowing organs at risk Dose optimisation Dysphagia
The authors wish to thank the speech pathology department and radiation therapy department at the Prince of Wales Hospital and Princess Alexandra Hospital for their contributions and support to this project. This project was funded by the Head and Neck Cancer Research Fund at Prince of Wales Hospital, Sydney Australia.
This project was funded by the Head and Neck Cancer Research Fund at Prince of Wales Hospital, Sydney Australia.
Compliance with Ethical Standards
Conflict of interest
All authors declares that he/she has no conflict of interest.
This article does not contain any studies with human participants performed by any of the authors.
- 5.Moroney LB, Helios J, Ward EC, Crombie J, Wockner LF, Burns CL, Spurgin AL, Blake C, Kenny L, Hughes BG. Patterns of dysphagia and acute toxicities in patients with head and neck cancer undergoing helical IMRT ± concurrent chemotherapy. Oral Oncol. 2017;64:1–8. https://doi.org/10.1016/j.oraloncology.2016.11.009.CrossRefGoogle Scholar
- 6.Bressan V, Stevanin S, Bianchi M, Aleo G, Bagnasco A, Sasso L. The effects of swallowing disorders, dysgeusia, oral mucositis and xerostomia on nutritional status, oral intake and weight loss in head and neck cancer patients: a systematic review. Cancer Treat Rev. 2016;45:105–19. https://doi.org/10.1016/j.ctrv.2016.03.006.CrossRefGoogle Scholar
- 7.Barnhart MK, Robinson RA, Simms VA, Ward EC, Cartmill B, Chandler SJ, Smee RI. Treatment toxicities and their impact on oral intake following non-surgical management for head and neck cancer: a 3-year longitudinal study. Support Care Cancer. 2018;26(7):2341–51. https://doi.org/10.1007/s00520-018-4076-6.CrossRefGoogle Scholar
- 8.Schindler A, Denaro N, Russi EG, Pizzorni N, Bossi P, Merlotti A, Spadola Bissetti M, Numico G, Gava A, Orlandi E, Caspiani O, Buglione M, Alterio D, Bacigalupo A, De Sanctis V, Pavanato G, Ripamonti C, Merlano MC, Licitra L, Sanguineti G, Langendijk JA, Murphy B. Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: literature review and consensus. Crit Rev Oncol Hematol. 2015;96(2):372–84. https://doi.org/10.1016/j.critrevonc.2015.06.005.CrossRefGoogle Scholar
- 9.Cohen EE, LaMonte SJ, Erb NL, Beckman KL, Sadeghi N, Hutcheson KA, Stubblefield MD, Abbott DM, Fisher PS, Stein KD, Lyman GH, Pratt-Chapman ML. American Cancer Society Head and neck cancer survivorship care guideline. CA Cancer J Clin. 2016;66(3):203–39. https://doi.org/10.3322/caac.21343.CrossRefGoogle Scholar
- 12.Roe JW, Drinnan MJ, Carding PN, Harrington KJ, Nutting CM. Patient-reported outcomes following parotid-sparing intensity-modulated radiotherapy for head and neck cancer. How important is dysphagia? Oral Oncol. 2014;50(12):1182–7. https://doi.org/10.1016/j.oraloncology.2014.09.009.CrossRefGoogle Scholar
- 13.Gupta T, Agarwal J, Jain S, Phurailatpam R, Kannan S, Ghosh-Laskar S, Murthy V, Budrukkar A, Dinshaw K, Prabhash K, Chaturvedi P, D’Cruz A. Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial. Radiother Oncol. 2012;104(3):343–8. https://doi.org/10.1016/j.radonc.2012.07.001.CrossRefGoogle Scholar
- 14.Marta GN, Silva V, de Andrade Carvalho H, de Arruda FF, Hanna SA, Gadia R, da Silva JL, Correa SF, Vita Abreu CE, Riera R. Intensity-modulated radiation therapy for head and neck cancer: systematic review and meta-analysis. Radiother Oncol. 2014;110(1):9–15. https://doi.org/10.1016/j.radonc.2013.11.010.CrossRefGoogle Scholar
- 15.Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A’Hern RP, Sydenham MA, Emson M, Hall E. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12(2):127–36. https://doi.org/10.1016/S1470-2045(10)70290-4.CrossRefPubMedCentralGoogle Scholar
- 16.Eisbruch A, Schwartz M, Rasch C, Vineberg K, Damen E, Van As CJ, Marsh R, Pameijer FA, Balm AJM. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys. 2004;60(5):1425–39. https://doi.org/10.1016/j.ijrobp.2004.05.050.CrossRefGoogle Scholar
- 18.Brouwer CL, Steenbakkers RJHM, Bourhis J, Budach W, Grau C, Grégoire V, van Herk M, Lee A, Maingon P, Nutting C, O’Sullivan B, Porceddu SV, Rosenthal DI, Sijtsema NM, Langendijk JA. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Radiother Oncol. 2015;117(1):83–90. https://doi.org/10.1016/j.radonc.2015.07.041.CrossRefGoogle Scholar
- 21.Vainshtein JM, Samuels S, Tao Y, Lyden T, Haxer M, Spector M, Schipper M, Eisbruch A. Impact of xerostomia on dysphagia after chemotherapy–intensity-modulated radiotherapy for oropharyngeal cancer: prospective longitudinal study. Head Neck. 2016;38(S1):E1605–12. https://doi.org/10.1002/hed.24286.CrossRefGoogle Scholar
- 22.Feng FY, Kim HM, Lyden TH, Haxer MJ, Worden FP, Feng M, Moyer JS, Prince ME, Carey TE, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A. Intensity-modulated chemoradiotherapy aiming to reduce Dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol. 2010;28(16):2732–8. https://doi.org/10.1200/jco.2009.24.6199.CrossRefPubMedCentralGoogle Scholar
- 23.Brodin NP, Kabarriti R, Garg MK, Guha C, Tome WA. Systematic review of normal tissue complication models relevant to standard fractionation radiation therapy of the head and neck region published after the QUANTEC reports. Int J Radiat Oncol Biol Phys. 2018;100(2):391–407. https://doi.org/10.1016/j.ijrobp.2017.09.041.CrossRefGoogle Scholar
- 24.van der Laan HP, Christianen MEMC, Bijl HP, Schilstra C, Langendijk JA. The potential benefit of swallowing sparing intensity modulated radiotherapy to reduce swallowing dysfunction: an in silico planning comparative study. Radiother Oncol. 2012;103(1):76–81. https://doi.org/10.1016/j.radonc.2011.11.001.CrossRefGoogle Scholar
- 25.van der Laan HP, Gawryszuk A, Christianen MEMC, Steenbakkers RJHM, Korevaar EW, Chouvalova O, Wopken K, Bijl HP, Langendijk JA. Swallowing-sparing intensity-modulated radiotherapy for head and neck cancer patients: treatment planning optimization and clinical introduction. Radiother Oncol. 2013;107(3):282–7.CrossRefGoogle Scholar
- 26.Christianen ME, van der Schaaf A, van der Laan HP, Verdonck-de Leeuw IM, Doornaert P, Chouvalova O, Steenbakkers RJ, Leemans CR, Oosting SF, van der Laan BF, Roodenburg JL, Slotman BJ, Bijl HP, Langendijk JA. Swallowing sparing intensity modulated radiotherapy (SW-IMRT) in head and neck cancer: clinical validation according to the model-based approach. Radiother Oncol. 2016;118(2):298–303. https://doi.org/10.1016/j.radonc.2015.11.009.CrossRefGoogle Scholar
- 28.Moroney LB, Helios J, Ward EC, Crombie J, Pelecanos A, Burns CL, Spurgin A, Blake C, Kenny L, Chua B, Hughes BG (In Press) Helical IMRT with concurrent chemotherapy for oropharyngeal SCC: a prospective investigation of acute swallowing and toxicity patterns. Head Neck Oncol.Google Scholar
- 29.Cilla S, Deodato F, Macchia G, Digesù C, Ianiro A, Piermattei A, Valentini V, Morganti AG. Volumetric modulated arc therapy (VMAT) and simultaneous integrated boost in head-and-neck cancer: is there a place for critical swallowing structures dose sparing? Br J Radiol. 2016;89(1059):20150764. https://doi.org/10.1259/bjr.20150764.CrossRefPubMedCentralGoogle Scholar
- 30.Brouwer CL, Steenbakkers RJHM, Gort E, Kamphuis ME, van der Laan HP, van’t Veld AA, Sijtsema NM, Langendijk JA. Differences in delineation guidelines for head and neck cancer result in inconsistent reported dose and corresponding NTCP. Radiother Oncol. 2014;111(1):148–52. https://doi.org/10.1016/j.radonc.2014.01.019.CrossRefGoogle Scholar
- 31.Garden AS, Beadle BM, Gunn GB. Radiotherapy for head and neck cancers indications and tehniques. 5th ed. Philadelphia: Wolters Kluwer; 2018.Google Scholar
- 32.Robbins K, Clayman G, Levine PA, et al. Neck dissection classification update: revisions proposed by the american head and neck society and the american academy of otolaryngology–head and neck surgery. Arch Otolaryngol Head Neck Surg. 2002;128(7):751–8. https://doi.org/10.1001/archotol.128.7.751.CrossRefGoogle Scholar
- 36.Schwartz DL, Hutcheson K, Barringer D, Tucker SL, Kies M, Holsinger FC, Ang KK, Morrison WH, Rosenthal DI, Garden AS, Dong L, Lewin JS. Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2010;78(5):1356–65. https://doi.org/10.1016/j.ijrobp.2009.10.002.CrossRefPubMedCentralGoogle Scholar
- 37.Petkar I, Rooney K, Roe JWG, Patterson JM, Bernstein D, Tyler JM, Emson MA, Morden JP, Mertens K, Miles E, Beasley M, Roques T, Bhide SA, Newbold KL, Harrington KJ, Hall E, Nutting CM. DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer. BMC Cancer. 2016;16(1):770. https://doi.org/10.1186/s12885-016-2813-0.CrossRefPubMedCentralGoogle Scholar